Nacuity Pharmaceuticals is a clinical-stage leader in innovative treatments for oxidative stress. The company’s powerful, targeted therapies aim to stop oxidative tissue damage, a driver of blinding eye diseases and a broad spectrum of serious chronic conditions. Nacuity has highly differentiated clinical programs, including retinitis pigmentosa, cataract, cystinosis and neurological diseases.
Nacuity seeks to expand the science and clinical potential for prescription products addressing diseases and conditions involving oxidative stress. This largely unaddressed disease mechanism is potentially a key factor in maladies ranging from ophthalmic diseases and conditions, both rare and prevalent, to many serious non-ophthalmic diseases and conditions associated with aging, neurodegeneration and cellular dysfunction.
Based in Fort Worth, TX, Nacuity is founded by veterans of Alcon Laboratories experienced in research, development, and commercialization of products to address ophthalmic diseases and conditions. The company’s core science is based on the extensive research of Dr. Peter Campochiaro of the Wilmer Eye Institute involving oxidative stress in the retina. Nacuity has key backing and technical support from Foundation Fighting Blindness and RD Fund, the world’s leading private funders of retinal disease research.
Mission & Vision
We aim to bring powerful, targeted treatments to underserved patient communities afflicted by blinding eye diseases and serious chronic conditions in which oxidative stress plays a role.
Leadership
Carol Lakkis, BScOptom, PhD, PGCertOcTher
Director/R&D Technical Director, Nacuity Pharmaceuticals, Pty, Ltd
